Having a large clinical trial portfolio means giving patients treatment options often not available anywhere else, and years before they become the standard of care. To learn more about Karmanos Cancer Institute clinical trials or to see if a trial is right for you, please call 1-800-KARMANOS (1-800-527-6266) or request an appointment below
  • Randomized, Double-Blinded Phase III Study of Cabozantinib versus Placebo in Patients with Advanced Neuroendocrine Tumors After Progression on prior therapy (CABINET)

    Cancer Categories
    • Gastrointestinal (GI)
    Karmanos Trial ID
    • A021602
    NCT ID
    • NCT03375320
    Age Group
    • Adult
    Scope
    • National
    PhaseClick for Clinical Trial Phase DefinitionPhase III
    Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug
    • Phase III
    Principal Investigator
    • Mohammed Najeeb
      Al Hallak, M.D., MS

      Oncology - Medical View Profile

    Objective:

    Primary Objectives:
    • To determine whether cabozantinib can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced pancreatic NET whose disease has progressed after treatment with everolimus.
    • To determine whether cabozantinib can significantly improve progression-free survival (PFS) compared to placebo in patients with advanced carcinoid tumors whose disease has progressed after treatment with everolimus.
    Secondary Objectives:
    • To determine whether cabozantinib can significantly improve overall survival (OS) compared to placebo in patients with advanced pancreatic NET whose disease has progressed after treatment with everolimus.
    • To determine whether cabozantinib can significantly improve overall survival (OS) compared to placebo in patients with advanced carcinoid tumors whose disease has progressed after treatment with everolimus.
    • To evaluate safety and tolerability of cabozantinib versus placebo in patients with advanced pancreatic NET using CTCAE and PRO-CTCAE.
    • To evaluate safety and tolerability of cabozantinib versus placebo in patients with advanced carcinoid tumors using CTCAE and PRO-CTCAE.
    • To evaluate the overall radiographic response rate of cabozantinib versus placebo in patients with advanced pancreatic NET whose disease has progressed after treatment with everolimus.
    • To evaluate the overall radiographic response rate of cabozantinib versus placebo in patients with advanced carcinoid tumors whose disease has progressed after treatment with everolimus.
  • Locations

    Locations

    Karmanos Cancer Institute - Detroit Headquarters

    4100 John R
    Detroit, MI 48201
    Get Directions
    Phone: 800-527-6266

    Karmanos Cancer Institute at McLaren Central Michigan, Morey Cancer Center

    1221 South Drive
    Mt Pleasant, MI 48858
    Get Directions
    Phone: 989-772-6811

    Karmanos Cancer Institute at McLaren Clarkston

    5680 Bow Pointe Dr
    Clarkston, MI 48346
    Get Directions
    Phone: 248-922-6650

    Karmanos Cancer Institute at McLaren Flint

    4100 Beecher Rd
    Flint, MI 48532
    Get Directions
    Phone: 810-342-3800

    Karmanos Cancer Institute at McLaren Flint - Singh and Arora

    4100 Beecher Road
    Flint, MI 48532
    Get Directions

    Karmanos Cancer Institute at McLaren Greater Lansing - Medical Oncology and Hematology

    3520 Forest Rd.
    Lansing, MI 48910
    Get Directions
    Phone: 517-975-9500

    Karmanos Cancer Institute at McLaren Macomb

    1080 Harrington Blvd
    Mount Clemens, MI 48043
    Get Directions
    Phone: 586-493-7500

    Karmanos Cancer Institute at McLaren Northern Michigan, Petoskey

    560 W Mitchell St
    Petoskey, MI 49770
    Get Directions
    Phone: 231-487-3390

    Karmanos Cancer Institute at McLaren Port Huron

    1221 Pine Grove Ave
    Port Huron, MI 48060
    Get Directions
    Phone: 810-982-5200

    Karmanos Cancer Institute at Weisberg Cancer Center - Farmington Hills

    31995 Northwestern Hwy
    Farmington Hills, MI 48334
    Get Directions
    Phone: 800-527-6266